NVIDIA's Third Growth Curve: Three Businesses Not Yet Visible in Its Financials
NVIDIA's third growth curve: valuing robotaxis, BioNeMo AI drug discovery, and Isaac robotics with an options framework—and confronting zero AI-drug approvals.
NVIDIA's third growth curve: valuing robotaxis, BioNeMo AI drug discovery, and Isaac robotics with an options framework—and confronting zero AI-drug approvals.
NVIDIA's golden decade: compare ROE at Wiwynn, Hon Hai, Quanta, Wistron, and Inventec using MOPS filings, the CoWoS chain, and the truth about Constellation.
NVIDIA (NVDA) deep dive: shares near record highs, yet the P/E is only 22x. Assess earnings quality, DSO up 15 days, and $279 billion in supply commitments.
Covered calls vs cash-secured puts: near-identical payoffs, but different capital, dividends and assignment — plus a four-filter entry checklist.
Exact position-sizing and stop-loss rules for US option sellers: 1%–1.5% per trade, 5% per underlying, Delta 0.25–0.30 entry, 0.40 cut, 0.55 full exit.
A map of the independent publishers doing long-form US equity moat research — four publisher types compared, a five-step vetting checklist, and the numeric thresholds to demand.

Revenue reaccelerated to 36% after 1,100 layoffs. The real question: is 44.5x EV/Revenue buying a CDN, or a toll-booth option on the machine-payment era?

A $117M GAAP operating loss spooked the market and sent the stock down 15-16% — but over a third of it is stock-based compensation. Revenue grew 48% YoY, accel…